Pluristem  placenta-based cell therapy products

Pluristem Therapeutics Inc. (PSTI) (PSTI.TA),

a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration (FDA) has cleared Pluristem’s Investigational Drug Application (IND) for a Phase III study of its PLX-PAD cell therapy in the treatment of muscle injury following surgical repair (arthroplasty) of the hip joint due to fracture. Pluristem is in discussions with several EU countries to approve this study in Europe as well and expects to begin patient enrollment in both regions during 2018. Non-dilutive funding totaling $8.7 million (7.4 million Euro) has been granted to this study from Horizon 2020, the European Union’s largest research and innovation program.

The Phase III study follows positive results from a Phase I/II trial which demonstrated significant muscle regeneration when using PLX-PAD cells in total hip arthroplasty patients.

stem cell cancer treatment success rate

The study demonstrated a 300% change in muscle volume (p=0.004) and a 500% (p=0.0067) change in muscle force at 6 months post-surgery, compared to the control group.




contract research organization

stem cell therapy